Longer-term results from the Phase 2 CELIA study suggest clinical benefit may build over time NEW YORK, Nov. 18, 2026 /PRNewswire/ — Today at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, Biogen presented new data from the Phase 2 CELIA study of diranersen…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

